Exhibit 10.3

SPONSOR SUPPORT AGREEMENT


This
SPONSOR SUPPORT AGREEMENT (this “Agreement”), dated as of April 28 2022, is entered into by and among Ignyte
Sponsor LLC, a Delaware limited liability company (the “Sponsor”), Ignyte Acquisition Corp., a Delaware corporation
(“Ignyte”), and Peak Bio Co., Ltd., a corporation organized under the laws of the Republic of Korea (the “Company”).
Capitalized terms used but not otherwise defined in this Agreement shall have the meanings ascribed to them in the BCA (as defined
below).


RECITALS


WHEREAS,
concurrently herewith, Ignyte, the Company, and Ignyte Korea Co., Ltd., a corporation organized under the laws of the Republic
of Korea, are entering into a Business Combination Agreement (as amended, supplemented, restated or otherwise modified from time
to time, the “BCA”), pursuant to which (and subject to the terms and conditions set forth therein) the parties
thereto are agreeing to, among other things, effect the Share Swap, and as a result, the Company will become a wholly-owned subsidiary
of Ignyte;


WHEREAS,
the Sponsor is currently the record owner of 1,437,500 shares of Ignyte Common Stock (the “Sponsor Shares”);
and 


WHEREAS, as a condition and inducement to the willingness of Ignyte and the Company to enter into the BCA, Ignyte,
the Company and the Sponsor are entering into this Agreement.


AGREEMENT


NOW,
THEREFORE, in consideration of the foregoing and the mutual covenants and agreements set forth herein, and for other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby,
the Sponsor, Ignyte and the Company hereby agree as follows:


1. Voting Agreement. The Sponsor agrees that, at the Ignyte
Stockholders’ Meeting, at any other meeting of the stockholders of Ignyte (whether annual or special and whether or not
an adjourned or postponed meeting, however called and including any adjournment or postponement thereof) and in connection with
any written consent of the stockholders of Ignyte, the Sponsor shall:


a. when such meeting is held, appear at such meeting or
otherwise cause the Sponsor Shares to be counted as present thereat for the purpose of establishing a quorum;


b. vote (or execute
and return an action by written consent), or cause to be voted at such meeting (or validly execute and return and cause such consent
to be granted with respect to), all of the Sponsor Shares in favor of (i) the approval and adoption of the BCA and approval of
the Business Combination and all other transactions contemplated by the BCA and (ii) against any action, agreement or transaction
or proposal that would result in a breach of any covenant, representation or warranty or any other obligation or agreement of
Ignyte under the BCA or that would reasonably be expected to result in the failure of the Business Combination from being consummated
and (iii) each of the proposals and any other matters necessary or reasonably requested by Ignyte for consummation of the Business
Combination and the other transactions contemplated by the BCA; and


c. vote (or execute and return an action by written consent),
or cause to be voted at such meeting (or validly execute and return and cause such consent to be granted with respect to), all
of the Sponsor Shares against (i) any Business Combination Proposal other than with the Company and (ii) any other action that
would reasonably be expected to (x) materially impede, interfere with, delay, postpone or adversely affect the Business Combination
or any of the other transactions contemplated by the BCA, or (y) result in a breach of any covenant, representation or warranty
or other obligation or agreement of the Sponsor contained in this Agreement.


2. Transfer of Shares.
Except as otherwise contemplated by the BCA or this Agreement, the Sponsor agrees that it shall not, directly or indirectly, (a)
sell, assign, transfer (including by operation of law), create any lien or pledge, dispose of or otherwise encumber any of the
Sponsor Shares or otherwise agree to do any of the foregoing, (b) deposit any Sponsor Shares into a voting trust or enter into
a voting agreement or arrangement or grant any proxy or power of attorney with respect
thereto that is inconsistent with this Agreement or (c) enter into any contract, option or other arrangement or undertaking requiring
the direct acquisition or sale, assignment, transfer or other disposition of any Sponsor Shares.


1








3.
No Solicitation of Transactions. The Sponsor agrees not to directly or indirectly, through any officer, director, representative,
agent or otherwise, (a) solicit, initiate or knowingly encourage (including by furnishing information) the submission of, or participate
in any discussions or negotiations regarding, any transaction in violation of the BCA or (b) participate in any discussions or
negotiations regarding, or furnish to any person or other entity or “group” within the meaning of Section 13(d) of
the Exchange Act, any information with the intent to, or otherwise cooperate in any way with respect to, or knowingly assist,
participate in, facilitate or encourage, any unsolicited proposal that constitutes, or may reasonably be expected to lead to,
a Business Combination Proposal or other transaction in violation of the BCA. Sponsor shall, and shall cause its affiliates and
Representatives to, immediately cease any and all existing discussions or negotiations with any person (other than with the Company,
its stockholders and their respective affiliates and Representatives) conducted prior to the date hereof with respect to, or which
is reasonably likely to give rise to or result in, a Business Combination Proposal. If the Sponsor receives any inquiry or proposal
with respect to a Business Combination Proposal, then Sponsor shall promptly (and in no event later than twenty-four (24) hours
after the Sponsor becomes aware of such inquiry or proposal) notify such person in writing that Ignyte is subject to an exclusivity
agreement with respect to the Business Combination that prohibits Sponsor from considering such inquiry or proposal.


4.
Representations and Warranties of the Sponsor. The Sponsor hereby represents and warrants to Ignyte and the Company as
follows:


a. The Sponsor is the only record and a beneficial owner (within the meaning of Rule 13d-3 under the Exchange Act) of,
and has good, valid and marketable title to, the Sponsor Shares, free and clear of Liens other than as created by this Agreement
or Sponsor’s organizational documents or the organizational documents of Ignyte (including, without limitation, for the
purposes hereof, any agreement between or among stockholders of Ignyte).


b. The Sponsor (i) has full voting power, full power
of disposition and full power to issue instructions with respect to the matters set forth herein, in each case, with respect to
the Sponsor Shares, (ii) has not entered into any voting agreement or voting trust with respect to any of the Sponsor Shares that
is inconsistent with the Sponsor’s obligations pursuant to this Agreement, (iii) has not granted a proxy or power of attorney
with respect to any of the Sponsor Shares that is inconsistent with the Sponsor’s obligations pursuant to this Agreement
and (iv) has not entered into any agreement or undertaking that is otherwise inconsistent with, or would interfere with, or prohibit
or prevent it from satisfying, its obligations pursuant to this Agreement.


c. The Sponsor (i) is a legal entity duly organized,
validly existing and, to the extent such concept is applicable, in good standing under the Laws of the jurisdiction of its organization
and (ii) has all requisite limited liability company or other power and authority and has taken all limited liability company
or other action necessary in order to, execute, deliver and perform its obligations under this Agreement and to consummate the
transactions contemplated hereby. This Agreement has been duly executed and delivered by the Sponsor and constitutes a valid and
binding agreement of the Sponsor enforceable against the Sponsor in accordance with its terms, subject to applicable bankruptcy,
insolvency, fraudulent conveyance, reorganization, moratorium and similar Laws affecting creditors’ rights generally and
subject, as to enforceability, to general principles of equity.


d. Other than the filings, notices and reports pursuant to, in
compliance with or required to be made under the Exchange Act, no filings, notices, reports, consents, registrations, approvals,
permits, waivers, expirations of waiting periods or authorizations are required to be obtained by the Sponsor from, or to be given
by the Sponsor to, or be made by the Sponsor with, any Governmental Authority in connection with the execution, delivery and performance
by the Sponsor of this Agreement, the consummation of the transactions contemplated hereby or the Business Combination and the
other transactions contemplated by the BCA.


e. The execution, delivery and performance of this Agreement by the Sponsor does not,
and the consummation of the transactions contemplated hereby or the Business Combination and the other transactions contemplated
by the BCA will not, constitute or result in (i) a breach or violation of, or a default under, the limited liability company agreement
or similar governing documents of the Sponsor, (ii) with or without notice, lapse of time or both, a breach or violation of, a
termination (or right of termination) of or a default under, the loss of any benefit under, the creation, modification or acceleration
of any obligations under or the creation of a Lien on any of the properties, rights or assets of the Sponsor pursuant to any contract
binding upon the Sponsor or, assuming (solely with respect to performance of
this Agreement and the transactions contemplated hereby), compliance with the matters referred to in Section 1, under any
applicable Law to which the Sponsor is subject or (iii) any change in the rights or obligations of any party under any contract
legally binding upon the Sponsor, except, in the case of clause (ii) or (iii) directly above, for any such breach, violation,
termination, default, creation, acceleration or change that would not, individually or in the aggregate, reasonably be expected
to prevent or materially delay or impair the Sponsor’s ability to perform its obligations hereunder or to consummate the
transactions contemplated hereby, the consummation of the Business Combination or the other transactions contemplated by the BCA.


2







f. As of the date of this Agreement, there is no action, proceeding or investigation pending against the Sponsor or, to the knowledge
of the Sponsor, threatened against the Sponsor that questions the beneficial or record ownership of the Sponsor Shares, the validity
of this Agreement or the performance by the Sponsor of its obligations under this Agreement.


g. The Sponsor understands and acknowledges
that each of Ignyte and the Company is entering into the BCA in reliance upon the Sponsor’s execution and delivery of this
Agreement and the representations, warranties, covenants and other agreements of the Sponsor contained herein


5. Further Assurances.
From time to time, at either Ignyte’s of the Company’s request and without further consideration, the Sponsor shall
execute and deliver such additional documents and take all such further action as may be reasonably necessary or reasonably requested
to effect the actions and consummate the transactions contemplated by this Agreement.


6.
Changes in Capital Stock. In the event of a stock split, stock dividend or distribution, or any change in Ignyte’s
capital stock by reason of any stock split, reverse stock split, recapitalization, combination, reclassification, exchange of
shares or the like, equitable adjustment shall be made to the provisions of this Agreement as may be required so that the intended
rights, privileges, duties and obligations hereunder shall be given full effect.


7.
Amendment and Modification. This Agreement may not be amended, modified or supplemented in any manner, whether by course
of conduct or otherwise, except by an instrument in writing signed by the Sponsor, Ignyte and the Company.


8.
Waiver. No failure or delay by any party hereto exercising any right, power or privilege hereunder shall operate as a waiver
thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any
other right, power or privilege. The rights and remedies of the parties hereto hereunder are cumulative and are not exclusive
of any rights or remedies which they would otherwise have hereunder. Any agreement on the part of a party hereto to any such waiver
shall be valid only if set forth in a written instrument executed and delivered by such party.


9.
Notices. All notices and other communications hereunder shall be in writing and shall be deemed given if delivered personally,
by email (with confirmation of receipt) or sent by a nationally recognized overnight courier service to the parties hereto at
the following addresses (or at such other address for a party as shall be specified by like notice made pursuant to this Section
9):


	 	if to Ignyte, to:	 
	 	 	 	 
	 	Ignyte Acquisition Corp.
 640 Fifth Avenue
 New York, NY	 
	 	Attention:	David Rosenberg,
    Co-Chief Executive Officer 

David J. Strupp, Jr., Co-Chief Executive Officer	 
	 	Email:	drosenberg@Ignytespac.com

    dstrupp@Ignytespac.com	 
	 	 	 	 
	 	with a copy to:


DLA Piper LLP (US)
 51 John F. Kenney Parkway
 Suite 120
 Short Hills, NJ 07078


	 


	 	Attention:	Andrew P. Gilbert; Scott A. Cowan	 
	 	Email:	andrew.gilbert@us.dlapiper.com; scott.cowan@us.dlapiper.com


3










	 	if to the Sponsor, to:	 
	 	 	 
	 	Ignyte Sponsor LLC 

    640 Fifth Avenue

    New York, NY	 
	 	Attention:	David Rosenberg, Co-Chief Executive Officer

    David J. Strupp, Jr., Co-Chief Executive Officer	 
	 	Email:	drosenberg@Ignytespac.com

    dstrupp@Ignytespac.com	 
	 	 	 
	 	if to the Company, to:	 
	 	 	 
	 	Peak Bio Co. Ltd.

    Building B #1009,

    670 Daewangpangyo-ro (Sampyeong-dong, U Space 2),

    Bundang-gu, Seongnam-si, Gyenggi-do

    Attention: Hoyoung Huh, MD, Ph.D., Chief Executive Officer

    Email: hoyoung.huh@ph-pharma.com	 
	 	 	 
	 	with a copy to:	 
	 	 	 
	 	Bae, Kim & Lee LLC

    13F, Tower B, Centropolis,

    26 Ujeongguk-ro, Jongno-gu, Seoul 03161

    Attention: Jung Min Jo

    Email: jungmin.jo@bkl.co.kr	 
	 	 	 
	 	and	 	 
	 	 	 
	 	BC Burr McCabe Law 

    584 Castro Street #882 

    San Francisco, CA 94114 

    Attention: Peter McCabe 

    Email: pmccabe@bcbmlaw.com	 


10.
Entire Agreement. This Agreement and the BCA constitute the entire agreement and supersede all prior agreements and understandings,
both written and oral, among the parties hereto with respect to the subject matter hereof and thereof.


11.
No Third-Party Beneficiaries. The Sponsor hereby agrees that its representations, warranties and covenants set forth herein
are solely for the benefit of Ignyte and the Company in accordance with and subject to the terms of this Agreement, and this Agreement
is not intended to, and does not, confer upon any person other than the parties hereto any rights or remedies hereunder, including,
without limitation, the right to rely upon the representations and warranties set forth herein, and the parties hereto hereby
further agree that this Agreement may only be enforced against, and any action that may be based upon, arise out of or relate
to this Agreement, or the negotiation, execution or performance of this Agreement may only be made against, the persons expressly
named as parties hereto.


12.
Governing Law and Venue.


a. This Agreement shall be governed by, interpreted under, and construed in accordance with the
internal laws of the State of Delaware applicable to agreements made and to be performed within the State of Delaware, without
giving effect to any choice-of-law provisions thereof that would compel the application of the substantive laws of any other jurisdiction.


4








b.
All legal actions and proceedings arising out of or relating to this Agreement shall be heard and determined exclusively in any
Delaware Chancery Court; provided, that if jurisdiction is not then available in the Delaware Chancery Court, then any
such legal Action may be brought in any federal court located in the State of Delaware or any other Delaware state court. The
parties hereto hereby (x) irrevocably submit to the exclusive jurisdiction of the aforesaid courts for themselves and with respect
to their respective properties for the purpose of any Action arising out of or relating to this Agreement brought by any party
hereto, and (y) agree not to commence any Action relating thereto except in the courts described above in Delaware, other than
with respect to any appellate court thereof and other than Actions in any court of competent jurisdiction to enforce any judgment,
decree or award rendered by any such court in Delaware as described herein. Each of the parties further agrees that notice as
provided herein shall constitute sufficient service of process and the parties further waive any argument that such service is
insufficient. Nothing in this Agreement will affect the right of any party to this Agreement to serve process in any other manner
permitted by Law. Each of the parties irrevocably and unconditionally waives, and agrees not to assert, by way of motion or as
a defense, counterclaim or otherwise, in any Action arising out of or relating to this Agreement or the transactions contemplated
hereby, (i) any claim that it is not personally subject to the jurisdiction of the courts in Delaware as described herein for
any reason, (ii) that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced
in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution
of judgment or otherwise) and (iii) that (A) the Action in any such court is brought in an inconvenient forum, (B) the venue of
such Action is improper or (C) this Agreement, or the subject matter hereof, may not be enforced in or by such courts.


c. Each
of the parties hereby waives to the fullest extent permitted by applicable Law any right it may have to a trial by jury with respect
to any litigation directly or indirectly arising out of, under or in connection with this Agreement or the transactions contemplated
hereby. Each of the parties (i) certifies that no representative, agent or attorney of any other party has represented, expressly
or otherwise, that such other party would not, in the event of litigation, seek to enforce that foregoing waiver and (ii) acknowledges
that it and the others hereto have been induced to enter into this Agreement by, among other things, the mutual waivers and certifications
in this Section 12(c).


13.
Assignment; Successors. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned
by any of the parties hereto in whole or in part (whether by operation of Law or otherwise) without the prior written consent
of the other party, and any such assignment without such consent shall be null and void. This Agreement shall be binding upon,
inure to the benefit of and be enforceable by the parties hereto and their respective successors and permitted assigns.


14.
Specific Performance. Each party acknowledges and agrees that the other parties hereto would be irreparably harmed and
would not have any adequate remedy at law in the event that any of the provisions of this Agreement were not performed in accordance
with their specific terms or were otherwise breached. Accordingly, each party agrees that the other parties hereto shall be entitled
to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of
this Agreement, this being in addition to any other remedy to which such parties are entitled at law or in equity.


15.
Severability. In the event that any provision of this Agreement or the application thereof becomes or is declared by a
court of competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement will continue in full force
and effect and the application of such provision to other persons or circumstances will be interpreted so as reasonably to effect
the intent of the parties hereto.


16.
Counterparts. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the
same agreement, it being understood that each party need not sign the same counterpart. This Agreement shall become effective
when each party shall have received a counterpart hereof signed by all of the other parties. Signatures delivered electronically
or by facsimile shall be deemed to be original signatures.


17.
Termination. This Agreement shall terminate upon the earliest of (a) the Closing of the Business Combination, (b) the termination
of the BCA in accordance with its terms, and (c) the time this Agreement is terminated upon the mutual written agreement of Ignyte,
the Company and the Sponsor.


[Signature Pages Follow]


5








IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed (where applicable, by their respective officers or other authorized persons thereunto duly authorized) as of the date first written above.


	 	IGNYTE:	 
	 	 	 
	 	IGNYE
                                         ACQUISITION CORP.
	 	 	 
	 	By:
                                         	/s/
                                         David Strupp	 
	 	Name:
                                         David Strupp	 
	 	Tile:
                                         Co-Chief Executive Officer
	 	 	 
	 	SPONSOR:	 
	 	 	 
	 	IGNYTE
                                         SPONSOR LLC
	 	 	 
	 	By:
                                         	/s/
                                         David Strupp	 
	 	Name:
                                         David Strupp	 
	 	Tile:
                                         Co-Chief Executive Officer



[Signature Page to Sponsor
Support Agreement]